Upstream Bio, Inc.
$6.69
The Read: Upstream Bio's stock declined about 12% after Phase 2 VALIANT asthma data disappointed, then rallied 13% on strong cash and Phase 3 plans, fell below support amid slower enrollment and cash concerns, but surged nearly 98% after a Q1 beat and positive Phase 2 COPD data.
Price
Overlays
Panel
UPB
Hover to view data
No Data